Annual General Meeting of shareholders in Carmel Pharma ab
At the AGM of shareholders in Carmel Pharma ab, which was held on 17th April, the following emerged:
• Chairman of the Board Per Carendi opened the AGM with some words commemorating Sven Avander, who passed away in February after a period of illness. From 2000 to 2005, Sven Avander was the CEO of the company, and before that a Member of the Board for 2 years. Per Carendi stressed Sven Avander’s sterling efforts towards the development of the company during the years he was active in the company. Sven Avander was remembered and honored by all at the AGM with a minute’s silence.
• In his presentation to the AGM, CEO Dan Pitulia stressed that customer interest in PhaSeal was increasing across all markets. He noted that those companies that had repositioned their products in order to compete with PhaSeal had continued to experience difficulties in establishing their products in the market, as additional independent scientific studies had shown that PhaSeal is the only product that meets the rigorous demands that must be placed on the handling of hazardous medications. Increased activity by several companies in this market segment has been only beneficial to the company, in that it has led to an increased knowledge of the inherent risks involved in the handling hazardous medications among potential new customers.
Dan Pitulia concluded that during 2007 the company had greatly increased its sales to customers and shown a positive earnings trend. During the first quarter of 2008, the increase in volume to the customer was over 25% and the company was turning a profit.
• The AGM re-elected the following Members to the Board: Per Carendi (Chairman) Mats Enegren, Thomas Eklund, Thomas Pollare, Peter Hentschel. In addition, one new Member was elected, Renee Aguir-Lucander. Mikael Johnsson and Lars Henriksson were re-elected as Deputy Board Members.
Chairman of the Board Per Carendi conveyed on behalf of the Board its thanks to Jan Larsson for the important work he had done during his ten years as a Member of the Board.
• The AGM decided to adopt the profit and loss account and balance sheet, and the Group’s profit and loss account and Group balance sheet, presented to the AGM, and in accordance with the Board’s and the CEO’s proposal (supported by the auditor) decided that the net profit for the year of SEK 6,720,743, the loss brought forward of SEK -10 575 302 and the share premium reserve of SEK 24,538,530, in total SEK 20,683,971, would be carried forward.
• The AGM decided to discharge from liability the Board Members and the CEO for the administration of the company during the financial year of 2007.
• On behalf of the participants at the meeting, the AGM’s chair Per Carendi thanked CEO Dan Pitulia and his colleagues for their hard and focused work in the company during 2007.
